Opinion|Videos|March 12, 2025
Looking Ahead With SCLC: ADCs and Other Novel Agents
Panelists discuss how emerging antibody-drug conjugate (ADC) data from TROPiCS-03 and IDeate-Lung01 suggest potential in extensive-stage small cell lung cancer (ES-SCLC), impacting sequencing with current therapies. T-cell engagers like BI 764532 and HPN328 may reshape treatment. MRI surveillance, per retrospective data and MAVERICK, offers an alternative to prophylactic cranial irradiation (PCI), though select factors may still justify PCI use.
Advertisement
Video content above is prompted by the following:
- What is your perspective on the emerging data for ADCs in this space? Where might these fit into the evolving treatment paradigm, and how would you sequence them with other available therapies?
- TROPiCS-03 (Saci): Dowlati A, et al. WCLC 2024. Abs OA04.04
- I-DXd (IDeate-Lung01): Rudin CM, et al. WCLC 2024. Abs OA04
- What are your thoughts on current strategies and emerging data surrounding T-cell engagers, and how might they impact the treatment landscape?
- BI 764532 (DAREON-8): Peters S, et al. ASCO 2024. Abs TPS8127
- HPN328: Choudhury N, et al. ESMO 2023. Abs 698P
- What evidence supports MRI surveillance as an alternative to PCI for brain metastasis management in ES-SCLC? What factors might still warrant PCI?
- Retrospective data: Chen Y, et al. Respir Res. 2022;23:274.
- MAVERICK trial: NCT04155034
Advertisement
Related to this article
An NDA seeks FDA approval of savolitinib plus osimertinib for EGFR-mutated NSCLC with MET overexpression or amplification after EGFR TKI therapy.
Daiichi Sankyo and Merck withdrew the I-DXd BLA in ES-SCLC after FDA discussions found phase 2 IDeate-Lung01 data insufficient for accelerated approval.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The FDA has cleared an sNDA updating the taletrectinib (Ibtrozi) label with new DOR data in TKI-naive patients with locally advanced or metastatic ROS1-positive NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
China's NMPA Approves Pirtobrutinib Across CLL
3
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
4
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
5